002923SZSE
🚨 Material Event

Announcement on Olmesartan Medoxomil API Obtaining CEP Certificate

Rundu Co., Ltd.··2 pages

✨ AI Summary

Zhuhai Rundu Pharmaceutical Co., Ltd. announced it received a Certificate of Suitability to the European Pharmacopoeia (CEP) for its Olmesartan Medoxomil API from EDQM. This certification signifies recognition of the API's quality and manufacturing process by European regulatory standards, facilitating market access and enhancing the company's brand image internationally. The company anticipates this will broaden its international market reach.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002923

Stock Abbreviation: Rundu Shares

Announcement No.: 2026-044

Zhuhai Rundu Pharmaceutical Co., Ltd.

Announcement on Olmesartan Medoxomil API Obtaining CEP Certificate

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false records, misleading statements, or significant omissions.

Recently, Zhuhai Rundu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received a Certificate of Suitability to the Monograph of the European Pharmacopoeia (hereinafter referred to as the "CEP Certificate") for its Olmesartan Medoxomil API, issued by the European Directorate for the Quality of Medicines & HealthCare (hereinafter referred to as "EDQM"). The relevant situation is hereby announced as follows:

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.